Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is APR-1051, which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition.
Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes.
It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response (“DDR”) target.
The company is headquartered in Doylestown, Pennsylvania.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Oren Gilad |
Contact Details
Address: 3805 Old Easton Road Doylestown, Pennsylvania 18902 United States | |
| Phone | 617 463 9385 |
| Website | aprea.com |
Stock Details
| Ticker Symbol | APRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001781983 |
| CUSIP Number | 03836J102 |
| ISIN Number | US03836J2015 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| John P. Hamill CPA | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
| Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President and Chief Scientific Officer |
| Brian Wiley | Senior Vice President of Corporate Development and Strategy |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
| Andrea Epstein | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | SCHEDULE 13G/A | Filing |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | 8-K | Current Report |